Loading…
Lakewood-Amedex Biotherapeutics, Inc. is projected to rise to $3.09 by 2027, a +43% move from its current price of $2.16. LABT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.93 | $2.16 | $2.42 | +0.06% |
| Aug 6 | $1.84 | $2.16 | $2.54 | +0.12% |
| Aug 7 | $1.77 | $2.16 | $2.64 | +0.18% |
| Aug 8 | $1.72 | $2.17 | $2.72 | +0.24% |
| Aug 9 | $1.68 | $2.17 | $2.80 | +0.30% |
| Aug 10 | $1.64 | $2.17 | $2.87 | +0.36% |
| Aug 11 | $1.60 | $2.17 | $2.94 | +0.42% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.60 | $2.17 | $2.94 | +0.42% |
| Week 2 | $1.42 | $2.18 | $3.35 | +0.83% |
| Week 3 | $1.29 | $2.19 | $3.70 | +1.25% |
| Week 4 | $1.20 | $2.20 | $4.03 | +1.67% |
| Week 5 | $1.12 | $2.21 | $4.35 | +2.09% |
| Week 6 | $1.05 | $2.21 | $4.66 | +2.52% |
| Week 7 | $0.9948 | $2.22 | $4.97 | +2.94% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lakewood-Amedex Biotherapeutics, Inc. is a clinical-stage biotechnology company that develops antimicrobial products in the United States. It offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs.
It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc.
in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Lakewood-Amedex Biotherapeutics, Inc. (LABT) currently trades at $1.93 per share and has a market capitalization of $3.38M. It ranks 5085 by market cap. The near-term outlook is reflected in the forecast starting in 2026, where min $1.85, avg $1.93, max $3.53 and sentiment is NEUTRAL.
The longer horizon shows a path of rising averages and bullish sentiment in several years, with notable upside in later periods.
A major floor 81.9% below — a decisive break under it would weaken the trend.
The nearest floor, 14.4% below — buyers have tended to step in here.
The nearest ceiling, 83.8% above — a clean break opens room to run.
A major ceiling 300.5% above — clearing it would confirm fresh momentum.
Key LABT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LABT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.11 | Buy | $2.12 | Buy |
| MA 10 | $2.34 | Sell | $2.25 | Sell |
| MA 20 | $2.38 | Sell | $2.32 | Sell |
| MA 50 | $1.86 | Buy | $2.65 | Sell |
| MA 100 | — | Neutral | — | Neutral |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.75 | Neutral |
| Stoch RSI (14) | 22.01 | Neutral |
| CCI (20) | -68.99 | Neutral |
| Williams %R (14) | -89.10 | Info |
| MACD (12,26,9) | -0.08 | Sell |
| ROC (12) | -16.87 | Sell |
| Bollinger %B (20,2) | 0.29 | Neutral |
| Stochastic %K (14) | 10.90 | Buy |
| TRIX (15) | 0.39 | Buy |
| Awesome (5,34) | -0.30 | Sell |
| Ultimate (7,14,28) | 20.58 | Buy |
| Momentum (10) | 0.13 | Buy |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 1.78 | Buy |
| ADX (14) | 18.36 | Neutral |
| ATR (14) | 0.27 | Info |
The near-term technical picture is NEUTRAL, with RSI14 at 30 and the stock trading in the vicinity of key levels. The 50-day simple moving average is $4.58, providing a sense of the intermediate trend level. Support is at $1.85 and resistance at $6.00, framing a 30-day range from $0.8933 to $4.17.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.85 | $2.16 | $3.90 | 0% | Neutral | |
| $2.03 | $3.09 | $5.08 | +43% | Bullish | |
| $1.95 | $3.29 | $5.91 | +52% | Bullish | |
| $1.60 | $2.96 | $5.67 | +37% | Bullish | |
| $1.26 | $2.54 | $5.13 | +18% | Neutral | |
| $1.23 | $2.70 | $5.69 | +25% | Bullish | |
| $1.23 | $2.72 | $5.97 | +26% | Bullish | |
| $1.54 | $3.42 | $7.77 | +58% | Bullish | |
| $1.81 | $4.01 | $9.23 | +86% | Bullish | |
| $1.81 | $4.01 | $9.23 | +86% | Bullish | |
| $2.23 | $4.96 | $11.40 | +130% | Bullish | |
| $3.25 | $7.22 | $16.60 | +234% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.85 | $2.16 | $2.96 | +0.00% |
| September 2026 | $1.90 | $2.37 | $3.14 | +9.89% |
| October 2026 | $1.78 | $2.28 | $3.10 | -3.95% |
| November 2026 | $1.87 | $2.44 | $3.39 | +6.92% |
| December 2026 | $2.07 | $2.74 | $3.90 | +12.59% |
Click any year to see its month-by-month LABT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, LABT is projected to trade between $1.85 and $3.90, averaging $2.16 — a potential gain of 0% from today's $2.16. Price action looks broadly range-bound.
Lakewood-Amedex Biotherapeutics, Inc.'s 2027 outlook centres on $3.09, within a $2.03 to $5.08 range. That is up +43% on the projected 2026 average. That marks a +43% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, LABT could reach as high as $5.91, with a base case around $3.29 and support toward $1.95 — roughly +52% from $2.16. Momentum favours further upside here.
Expect LABT to range from $1.60 to $5.67 through 2029. The $2.96 average target implies a +37% move from current prices. That is -10% versus the projected 2028 average. Buyers look set to stay in control over this stretch.
The LABT price prediction for 2030 points to an average of $2.54 (low $1.26, high $5.13) — a potential gain of +18% on today's $2.16. Price action looks broadly range-bound.
In 2031, LABT is projected to trade between $1.23 and $5.69, averaging $2.70 — a potential gain of +25% from today's $2.16. That is up +6% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Lakewood-Amedex Biotherapeutics, Inc.'s 2032 outlook centres on $2.72, within a $1.23 to $5.97 range. That is up +1% on the projected 2031 average. That marks a +26% change versus current levels. Momentum favours further upside here.
By 2033, LABT could reach as high as $7.77, with a base case around $3.42 and support toward $1.54 — roughly +58% from $2.16. Buyers look set to stay in control over this stretch.
Expect LABT to range from $1.81 to $9.23 through 2034. The $4.01 average target implies a +86% move from current prices. That is up +17% on the projected 2033 average. Momentum favours further upside here.
The LABT price prediction for 2035 points to an average of $4.01 (low $1.81, high $9.23) — a potential gain of +86% on today's $2.16. Buyers look set to stay in control over this stretch.
In 2040, LABT is projected to trade between $2.23 and $11.40, averaging $4.96 — a potential gain of +130% from today's $2.16. That is up +24% on the projected 2035 average. Momentum favours further upside here.
Lakewood-Amedex Biotherapeutics, Inc.'s 2050 outlook centres on $7.22, within a $3.25 to $16.60 range. That is up +46% on the projected 2040 average. That marks a +234% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in LABT today (≈ 462.962963 LABT) could be worth
$3,342.3
+$2,342.3 (+234%) by 2050 · US Dollar
Based on the average projected LABT price of $7.22 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LABTwould be worth at today's price.
$1,000 invested in LABT on Apr 23, 2026 (≈ 115.606942 LABT) would be worth
$249.71
-$750.29 (-75.0%) today · 0.25× · US Dollar
Based on a LABT entry price of $8.65 vs. today's $2.16.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.64 | $818.18 | -18.2% |
| 1 month ago | $3.3 | $654.55 | -34.5% |
| 3 months ago | $3.43 | $629.74 | -37.0% |
| All time ago | $8.65 | $249.71 | -75.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LABT forecast.
Our base-case forecast reaches $4.30 around 2040.
Implied market cap at $4.30: $7.53M
Looking across the multi-year forecast, LABT shows a mix of modest early-years and stronger later upside. The 2026 forecast is min $1.85, avg $1.93, max $3.53 with ROI 0 and sentiment NEUTRAL. In 2027 the avg rises to $2.75 with ROI 42.3 and sentiment BULLISH, and 2028 shows avg $2.95 with ROI 52.9 and sentiment BULLISH, while 2029 has avg $2.65 with ROI 37.3 and sentiment BULLISH.
For 2030 the min is $1.11, avg $2.25, max $4.54 with ROI 16.6 and sentiment NEUTRAL.
Tap a question to reveal the answer.
The 2030 forecast lists min $1.11, avg $2.25, max $4.54 with ROI 16.6 and sentiment NEUTRAL.
The forecast spans neutral in 2026 and 2030, with bullish sentiment and higher averages in 2027–2029 and again in later years. Notable ROIs include 42.3 (2027), 52.9 (2028), 37.3 (2029), 131.8 (2040), and 235.7 (2050), indicating potential upside alongside substantial uncertainty.
Yes, the max forecasts show $🎯10.29 for 2040 and $14.90 for 2050, indicating the potential to reach around $10.29 by 2040, with higher upside possible in later years.
Current price is $1.93 and market cap is $3.38M.
The 30-day range was from a low of $0.8933 to a high of $4.17.
Lakewood-Amedex Biotherapeutics, Inc. Community Discussion
0Share your Lakewood-Amedex Biotherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.